KT-295 / Kymera Therap - LARVOL DELTA

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) - "In May, the Company made the strategic decision not to advance KT-295, its oral TYK2 degrader, into clinical development, despite completing IND-enabling studies with no adverse findings. This decision will allow Kymera to focus its team and financial resources on other pipeline programs, including KT-621 and KT-579."

Pipeline update • Atopic Dermatitis • Immunology

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire) - "Key upcoming KT-621 milestones: Complete KT-621 Phase 1 healthy volunteer clinical trial and report data in the second quarter of 2025. Advance KT-621 into a Phase 1b clinical trial in AD patients in the second quarter of 2025 and report data in the fourth quarter of 2025. Initiate KT-621 Phase 2b clinical trial in AD in the fourth quarter of 2025, followed by a Phase 2b clinical trial in asthma in early 2026. Key upcoming KT-295 milestones: File KT-295 IND and initiate dosing in the Phase 1 healthy volunteer clinical trial in the second quarter of 2025, with Phase 1 data expected in the fourth quarter of 2025."

IND • New P1 trial • New P2b trial • P1 data • Asthma • Atopic Dermatitis • Inflammatory Bowel Disease • Psoriasis